Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 62-69

  Soussi, Thierry ^a   Asselain, Bernard ^b   Hamroun, Dalil ^c   Kato, Shunsuke ^d   Ishioka, Chikashi ^d   Claustres, Mireille ^c   Béroud, Christophe ^c  

^a HÔPITAL TENON   (France)

^b INSTITUT CURIE   (France)

^c UNIV MONTPELLIER   (France)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; DNA; PROTEIN P53; RNA;

ARTICLE; ARTIFACT; BLADDER CARCINOMA; BRAIN CANCER; BREAST CARCINOMA; COLORECTAL CARCINOMA; DATA BASE; DNA SEQUENCE; ESOPHAGUS CARCINOMA; GENE MUTATION; GENETIC VARIABILITY; HEAD AND NECK CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS; METHODOLOGY; MOLECULAR CLONING; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STOMACH CARCINOMA; SYSTEMATIC ERROR; TUMOR SUPPRESSOR GENE;

DATABASES, FACTUAL; HUMANS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 29744446941     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0413     Document Type: Article

References (22)

1. Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40.
2. Soussi T. The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol Med Today 1996;2:32-7.
3. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
4. Soussi T. p53 mutations and resistance to chemotherapy: a stab in the back for p73? Bull Cancer 2003;90:383-6.
5. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990;4:1-8.
6. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 1993;4:42-6.
7. Milner J. Flexibility: the key to p53 function? Trends Biochem Sci 1995;20:49-51.
8. Soussi T, Béroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat 2003;21:192-200.
9. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-9.
10. Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005;25:6-17.
11. Rodin SN, Rodin AS. Human lung cancer and p53: the interplay between mutagenesis and selection [In Process Citation]. Proc Natl Acad Sci U S A 2000;97:12244-9.
12. Hainaut P, Pfeifer GP. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-74.
13. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat 2003;21:301-6.
14. Fattorini P, Ciofuli R, Cossutta F, et al. Fidelity of polymerase chain reaction-direct sequencing analysis of damaged forensic samples. Electrophoresis 1999;20:3349-57.
15. Wong C, DiCioccio RA, Allen HJ, Werness BA, Piver MS. Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation. Cancer Genet Cytogenet 1998;107:21-7.
16. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
17. Bitton A, Neuman MD, Glantz SA. The p53 tumour suppressor gene and the tobacco industry: research, debate and conflict of interest. Lancet 2005;365:1-10.
18. Dequeker E, Ramsden S, Grody WW, Stenzel TT, Barton DE. Quality control in molecular genetic testing. Nat Rev Genet 2001;2:717-23.
19. Claustres M, Horaitis O, Vanevski M, Cotton RG. Time for a unified system of mutation description and reporting: a review of locus-specific mutation databases. Genome Res 2002;12:680-8.
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
21. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
22. van Bokhoven H, McKeon F. Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol Med 2002;8:133-9.